Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28191)	2/14/1999 1:53:00 PM
From: Arthur Radley	Respond to of 32384

SmithKline had 1998 global pharmaceutical revenues of $7.7 billion, led by antibiotic Augmentin with sales of $1.6 billion and anti-depressant Paxil with sales of $1.75 billion. Avandia has received fast-track review by the FDA and could hit U.S. drugstores by June, said Neil Sweig, an analyst for Southeast Research Partners. He said Actos could be launched a few months later if it also wins six-month priority FDA review. Sweig noted that Rezulin is now administered alone or in combination with insulin. But he predicted Rezulin, Avandia and Actos within a few years will each be given alone or in an array of possible combinations -- with insulin, with Bristol-Myers Squibb Co. drug Glucophage (metformin) or with members of the older sulfonylurea class of drugs that includes Pfizer Inc.'s Glucotrol XL. By mistake I left out the above from the previous posting. -------------------------------------------------------------------------------- Feb 13 \| Feb 12 \| Feb 11 \| Feb 10 \| Feb 09 \| Feb 08 \| Feb 07 \| Feb 06 \|